99 related articles for article (PubMed ID: 18718649)
1. Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients.
Ferrandina G; Martinelli E; Petrillo M; Prisco MG; Zucconi A; Santaguida S; Zannoni G; Scambia G; Ferlini C
Gynecol Oncol; 2008 Nov; 111(2):237-43. PubMed ID: 18718649
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Cheng HL; Liu HS; Lin YJ; Chen HH; Hsu PY; Chang TY; Ho CL; Tzai TS; Chow NH
Br J Cancer; 2005 May; 92(10):1906-14. PubMed ID: 15870710
[TBL] [Abstract][Full Text] [Related]
3. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract.
Compérat E; Roupret M; Chartier-Kastler E; Bitker MO; Richard F; Camparo P; Capron F; Cussenot O
J Urol; 2008 Mar; 179(3):868-72; discussion 872. PubMed ID: 18221954
[TBL] [Abstract][Full Text] [Related]
5. Elevated RON protein expression in endometriosis and disease-associated ovarian cancers.
Xu P; Ding S; Zhu L; Le F; Huang X; Tian Y; Zhang X
Arch Gynecol Obstet; 2017 Mar; 295(3):631-639. PubMed ID: 27888297
[TBL] [Abstract][Full Text] [Related]
6. Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
Kim N; Cho SB; Park YL; Park SY; Myung E; Kim SH; Yu HM; Son YA; Myung DS; Lee WS; Joo YE
Oncol Rep; 2016 Jun; 35(6):3331-40. PubMed ID: 27035413
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma.
Wang SL; Weng DF; Wei HX; Huang Z; Lin RQ; Shi K; Lin JH
J Orthop Sci; 2021 Nov; 26(6):1100-1106. PubMed ID: 32972820
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer.
Lee CT; Chow NH; Su PF; Lin SC; Lin PC; Lee JC
Dis Colon Rectum; 2008 Aug; 51(8):1268-74. PubMed ID: 18536971
[TBL] [Abstract][Full Text] [Related]
9. Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.
Yu H; Yuan J; Xiao C; Qin Y
Int J Mol Med; 2013 May; 31(5):1248-54. PubMed ID: 23483216
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma.
Watanabe H; Yokoyama Y; Kokuryo T; Ebata T; Igami T; Sugawara G; Mizuno T; Shimoyama Y; Nagino M
Ann Surg Oncol; 2015 Jul; 22(7):2235-42. PubMed ID: 25586241
[TBL] [Abstract][Full Text] [Related]
11. Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer.
Yoon TM; Kim SA; Park YL; Lee KH; Sung MW; Lee JK; Lim SC; Chung IJ; Joo YE
Head Neck; 2013 Aug; 35(8):1106-13. PubMed ID: 22887469
[TBL] [Abstract][Full Text] [Related]
12. The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma.
Hayashi Y; Yamaguchi J; Kokuryo T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Nagino M
Anticancer Res; 2016 Dec; 36(12):6585-6592. PubMed ID: 27919987
[TBL] [Abstract][Full Text] [Related]
13. Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.
Liu YZ; Han DT; Shi DR; Hong B; Qian Y; Wu ZG; Yao SH; Tang TM; Wang MH; Xu XM; Yao HP
World J Gastrointest Oncol; 2020 Nov; 12(11):1216-1236. PubMed ID: 33250957
[TBL] [Abstract][Full Text] [Related]
14. RON (recepteur d'origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma.
Kim SA; Yoon TM; Lee DH; Park YL; Lee KH; Lim SC; Joo YE; Lee JK
Auris Nasus Larynx; 2014 Apr; 41(2):201-6. PubMed ID: 24287326
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
Ferrandina G; Petrillo M; Carbone A; Zannoni G; Martinelli E; Prisco M; Pignata S; Breda E; Savarese A; Scambia G
Br J Cancer; 2008 Jun; 98(12):1910-5. PubMed ID: 18506140
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance and prognostic value of RON protein expression in gastric carcinoma].
Zhou DH; Yian LP; Zheng C; Teng XD; Xu LJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1746-9. PubMed ID: 19035083
[TBL] [Abstract][Full Text] [Related]
17. RON and cisplatin resistance in ovarian cancer cell lines.
Prislei S; Mariani M; Raspaglio G; Mozzetti S; Filippetti F; Ferrandina G; Scambia G; Ferlini C
Oncol Res; 2010; 19(1):13-22. PubMed ID: 21141737
[TBL] [Abstract][Full Text] [Related]
18. Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression.
Yang SY; Nguyen TT; Ung TT; Jung YD
Chonnam Med J; 2017 Sep; 53(3):178-186. PubMed ID: 29026705
[TBL] [Abstract][Full Text] [Related]
19. Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor.
Montero-Julian FA; Dauny I; Flavetta S; Ronsin C; André F; Xerri L; Wang MH; Marvaldi J; Breathnach R; Brailly H
Hybridoma; 1998 Dec; 17(6):541-51. PubMed ID: 9890710
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
